Your browser doesn't support javascript.
loading
Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina, Shanly C; Lobbezoo, Dorien J A; de Boer, Maaike; Dercksen, M Wouter; van den Berkmortel, Franchette; van Kampen, Roel J W; van de Wouw, Agnès J; de Vries, Bart; Joore, Manuela A; Peer, Petronella G M; Voogd, Adri C; Tjan-Heijnen, Vivianne C G.
Afiliação
  • Seferina SC; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Lobbezoo DJ; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • de Boer M; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Dercksen MW; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • van den Berkmortel F; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • van Kampen RJ; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • van de Wouw AJ; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • de Vries B; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Joore MA; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Peer PG; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Voogd AC; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
  • Tjan-Heijnen VC; Departments of Medical Oncology, Pathology, Clinical Epidemiology and Medical Technology Assessment, and Epidemiology and GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Internal Medicine, Máxima Medical Centre, Vel
Oncologist ; 20(8): 856-63, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26099745
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article